Reducing Fungal Exposure Critical for Treating Rhinosinusitis with or without Polyps [Response to Letter]

Click to increase image sizeClick to decrease image size

Disclosure

Professor Claus Bachert reports personal fees from and is Principal Investigator of study and advisory board for GSK, Principal Investigator of studies for AstraZeneca and Sanofi, consulting for Mylan, consulting and presentations for ALK, outside the submitted work; and is an advisory board member of ALK, AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi.

Dr Neil Bhattacharyya reports personal fees from Sanofi outside the submitted work and is a consultant for Sanofi.

Dr Martin Desrosiers reports personal fees from GlaxoSmithKline, grants from Sanofi and Regeneron, advisory board, speaker bureau, and clinical investigator for GlaxoSmithKline, Sanofi and Regeneron, and AstraZeneca, during the conduct of the study; is a major equity holder of Probionase Therapies outside the submitted work; has received clinical trial funding from AstraZeneca, GlaxoSmithKline, Probionase Therapies, and Sanofi; and is an advisory board member of Regeneron Pharmaceuticals, Inc. and Sanofi.

Dr Asif H Khan reports being an employee of Sanofi, during the conduct of the study and may hold stock and/or stock options.

Additional information

Funding

Medical writing/editorial assistance was provided by Matt Lewis, PhD of Adelphi Group, Macclesfield, UK, in accordance with Good Publication Practice (GPP3) guidelines and funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.